Combination therapy for relapsed peripheral T-cell lymphoma: is two better than one?
Mené en Asie sur 25 patients atteints d'un lymphome T périphérique récidivant ou réfractaire, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité d'un traitement combinant panobinostat et bortézomib
Compared with their B-cell counterpart, most peripheral T-cell lymphomas have a dismal prognosis. Except for ALK-positive anaplastic large-cell lymphoma, the proportion of patients with peripheral T-cell lymphomas who survive for 10 years barely exceeds 15%.1 Up to now, no consensus has been reached as to the best treatment to be applied either in first line or at relapse. In frontline settings, all regimens built on the cyclophosphamide, vincristine, doxorubicin, and prednisolone backbone with or without etoposide have led to disappointing results.
The Lancet Haematology , commentaire, 2014